Record growth masks capex intensity, Xanthine guidance cut signals caution

₹610.5 Cr delivered, YoY +45.9%; 0.4% variance and 1.1% YoY variance within rounding

₹71.5 Cr delivered (8.3% higher), YoY +156%; management understated actual PAT

Margins healthy vs 17.7% prior year; Q2 at lower end of 22-25% guidance range

QoQ revenue +13.9% but PAT -6.1%, indicating margin/mix shift; Xanthine guidance cut to ₹900-₹1,100 Cr FY27 vs ₹1,220 run-rate Q1

CDMO stated as 13% of Q2 revenue = ~₹79 Cr; no Q1 CDMO absolute given; growth claim unverified

Q1 implied run-rate ₹1,220 Cr → FY27 guided ₹900-₹1,100 Cr (₹1,000 Cr midpoint). Attributed to price normalization as raw material costs subside; -₹120 Cr midpoint cut is material (~12% downgrade).

Reaffirmed 40-50% growth FY27-FY28; 59 projects, 39 commercial, 20 development; two major molecules launching next year. No upgrade or cut from prior guidance.

22-25% FY27 maintained from prior call; Q2 at 22.2% (lower end); raw material pass-through expected to improve Q3-Q4 margins back toward range.

₹1,000 Cr long-term API target unchanged; near-term growth hedged (10-15% annually on API+intermediate); current ~₹180 Cr run-rate.

₹350-400 Cr FY27 total (₹150 Cr H1, ₹250+ Cr H2); Atali and Xanthine capacity expansion continuing; no change from prior stated capex plans.

Atali Phase 1 complete; Phase 1B trials underway, commercialization H2 FY28. Xanthine expansion two-phase; first phase finished, second ramping. Full capitalization by year-end.

CDMO sales nearly doubled Q1. Xanthine and allied chemistry normally pass costs on. Q3-Q4 should catch up on pass-through pricing.

If prices remain high, ₹1,400-₹1,500 Cr at full capacity. Currently near 7,000 out of 9,600 units. Will gradually reach 90% over two years.

API+intermediate currently ₹180 Cr run-rate. Growth largely volume-driven. CDMO growth also helping. De-bottlenecking of steroid block underway, Q2 onwards improved sales.

Products for antihypertensive, pain management, anti-cancer, CNS; varied range. Peptide lab set up by end FY27; commercial customer business expected FY28.

Prices up 10-15% YoY average. Overall 15%-20% jump expected this year on volume. Utilization: 7,000 near-term, gradually 8,800-9,600 in two years.

Shipment issue caused ~5% Q2 spillover. CDMO growth 40-50% maintained — confident on guidance. Third, fourth quarter should see higher CDMO sales.

Xanthine realization softened slightly due to allied chemistry mix. Overall allied products saw higher turnover. More debt needed beyond H1; financing arranged for capex.

Not upgrading FY27 guidance; giving 3-year guidance only. Growth dependent on new product approvals. R&D investment increasing. This year looks promising.

Target ₹1,000 Cr CDMO revenue; 100 million molecules; whichever first. Depend on customer approvals. 59 projects, good potential. Fairly confident to achieve.

Lab operational by end FY27. Too early to give numbers or guidance. Question next year better.

61 APIs; several patent expires expected next year to launch in partners' markets. Strong Onco portfolio. Peptides, oligonucleotides large molecules; developing modalities. Few modalities, linkers, ADC linkers; will be offered.

Don't give that segment breakup currently.

H1 delivered 45.9% growth; H2 would need to decelerate sharply for full-year 15-18%. Management suggests full-year will be 'higher' than this. Guidance outdated or very conservative.

Down from ₹1,220 Cr Q1 run-rate; attributed to price normalization as raw materials stabilize. Implies H2 Xanthine ~₹305-350 Cr (flat to modest growth).

Implies ~₹280-300 Cr CDMO run-rate by FY29-30; 40-50% growth maintained for next 2 years. Dependent on customer approvals and project commercialization.

Current ~₹180 Cr run-rate; 5-year+ horizon. Management declined to quantify FY27-FY28 API growth, hedging on approval timelines.

Q2 delivered 22.2% (within range, lower end). Raw material cost pass-through expected to aid Q3-Q4. Capex depreciation and CDMO growth (higher margin) should support margins.

Capex depreciation starting H2; operating leverage from higher sales expected to expand margins 100-150bp into FY28.

H1 ~₹150 Cr deployed; H2 ₹250+ Cr planned for Atali (steroid API) and Xanthine expansion. Management confirmed 'more debt needed' for H2 capex.

Phase 1A complete; Phase 1B trials underway. Full utilization phased in H2 FY28 onwards.

Xanthine prices up 10-15% YoY but normalized guidance (₹900-₹1,100 Cr) implies price pressure ahead. Crude and China export tariffs could impact cost structure. Pass-through to customers lagging by 1-2 quarters.

59 CDMO projects, 39 commercial stage, 20 development; 40-50% growth target depends on timely customer approvals and successful scaling. Failed or delayed projects could derail revenue growth.

Inventories and receivables surging with 45%+ revenue growth; 150-167 day cash conversion cycle means ₹610 Cr revenue requires ~₹250 Cr+ working capital. Q2 CFO only ₹30 Cr (22% of EBITDA) signals stress.

Short-term borrowing already ₹650 Cr; H2 capex needs ₹250+ Cr more debt. Total debt rising sharply; interest burden increasing with rates; refinancing risk if capex doesn't generate FCF quickly.

API% of revenue declining (43% FY25 → 30% FY27); API long-term target ₹1,000 Cr has no near-term path. Mix shifting to lower-margin CDMO and intermediate products; growth driver lacks visibility.